Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 12 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Colorectal cancer	Gastroenterology , Oncology	2022	View \| Download
Pembrolizumab with Lenvatinib and chemotherapy for previously untreated advanced or metastatic gastroesophageal adenocarcinoma	Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Gastroesophageal adenocarcinoma	Gastrointestinal Cancer	2023	View \| Download
Pembrolizumab in combination with lenvatinib, platinum chemotherapy, and pemetrexed for non-small cell lung cancer	Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Pembrolizumab in combination with lenvatinib for advanced melanoma – first line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Melanoma	Skin Cancer	2021	View \| Download
Pembrolizumab in addition to lenvatinib for PD-L1 positive (at least 1%) non-small-cell lung cancer – first line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Lenvatinib with pembrolizumab for the treatment of squamous cell carcinoma of the head and neck	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Head and neck cancer , Squamous cell carcinoma (SCC)	Head and Neck Cancer	2022	View \| Download
Lenvatinib with pembrolizumab for previously treated metastatic non-small cell lung cancer	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Lenvatinib in combination with pembrolizumab for advanced/unresectable hepatocellular carcinoma – first-line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Lenvatinib in combination with Pembrolizumab for advanced or recurrent endometrial cancer - First Line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Endometrial cancer	Female Reproductive Cancer	2021	View \| Download
Lenvatinib in combination with pembrolizumab for advanced endometrial cancer – second line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Endometrial cancer	Female Reproductive Cancer	2020	View \| Download